A Utah-based biotechnology firm, Paterna Biosciences, announced Thursday it has successfully cultivated functional human sperm in a laboratory setting and used this lab-grown sperm to fertilize eggs, producing visibly healthy-looking embryos. This development could eventually provide a viable pathway for men facing certain types of infertility to have biological children, a goal scientists have pursued for nearly a century, according to company statements. The findings, though yet to undergo independent peer review, mark a significant step in reproductive medicine.
Paterna Biosciences achieved this milestone by isolating sperm-making stem cells from testicular tissue. The company then developed a method to nurture these cells in a dish, coaxing them into becoming fully developed sperm. This intricate process directly addresses a long-standing challenge in reproductive science, a field that has seen scientists attempt to produce sperm outside the body, a technique known as in vitro spermatogenesis, for nearly 100 years.
The company's CEO, Alexander Pastuszak, a board-certified urologist and associate professor at the University of Utah School of Medicine, explained that his team identified the precise molecular signals required to guide these stem cells through maturation. This is a complex biological journey. The natural process of sperm formation in the body takes a little over two months.
It involves several distinct stages within the tightly coiled tubules of the testicles. Stem cells first undergo meiosis, dividing to create cells with 23 chromosomes. During this phase, sperm also develop their distinctive tail and head structure, essential for movement.
They then migrate to another section of the testicles to gain motility. Finally, the vas deferens transports the mature sperm for release. “There are very strict control mechanisms at every single one of those steps,” Pastuszak told Reuters. “We’ve figured out the instructions that are needed to teach these stem cells to become mature, normal sperm.” This represents a significant biological achievement. Historically, creating viable human sperm in a lab has proven far more difficult than for other species.
A Japanese research team first successfully produced viable mouse sperm in a laboratory setting in 2011. While another French biotech company, Kallistem, claimed to achieve in vitro spermatogenesis in 2015, some external researchers questioned the full development of the sperm. That company also did not provide proof that its lab-made sperm could fertilize eggs.
Paterna's approach differs. They initially explored culturing entire testicular tubules but found nurturing only the stem cells more effective. Their team utilized computational biology to predict molecular signals crucial at each stage of sperm development, then tested various combinations of molecules to induce these stages until they found the optimal mixture.
This was a painstaking effort. Larry Lipshultz, a professor of urology at Baylor College of Medicine, who is not affiliated with Paterna, described the development as “huge.” He noted the longstanding difficulty in identifying the necessary growth factors to prompt stem cells to mature into sperm. “People didn't understand, or had never figured out, what growth factors you have to supply to these cells to get them to become mature sperm. Apparently, they've identified these substances,” Lipshultz explained.
His comments underscore the scientific community’s recognition of the complexity involved in this biological feat. The implications for families are substantial. Male factors contribute to roughly half of all infertility cases globally.
These issues range from low sperm count and abnormal sperm shape to poor sperm motility. A particularly challenging group comprises 10 to 15 percent of infertile men who have a complete absence of sperm in their ejaculate. For these individuals, options for having biological children have been severely limited.
Pastuszak indicates that while these men do not produce sperm, they often still possess the stem cells that give rise to sperm. Research from Paterna and other groups suggests that the issue often lies not with the stem cells themselves, but with the surrounding microenvironment that supports their development. By replicating a healthy environment in the lab, Paterna aims to produce healthy sperm.
This offers a new avenue for hope. The emotional toll of infertility on individuals and couples is immense. Ryan Flannigan, a surgeon specializing in sperm retrieval at the Vancouver Prostate Centre in Canada, who is not involved with Paterna, highlighted this burden. “You see the emotional toll and the impact on these individuals and couples,” Flannigan stated.
Current treatments for men with reduced sperm quantity or quality include certain medications, intrauterine insemination (IUI), and conventional in vitro fertilization (IVF). However, for men who produce no sperm at all, the treatment landscape becomes much narrower. Existing options for them often involve a surgical procedure to search for sperm directly within testicular tissue.
This surgery requires general anesthesia and can last up to four hours, depending on how quickly sperm are located. Even with such invasive measures, surgeons fail to find sperm in a significant percentage of cases. This is a difficult reality for many families.
Paterna's technology seeks to replace this invasive surgical process. Instead, it would require only a small biopsy of testicular tissue, which could be performed in a doctor’s office. This tissue would then be sent to Paterna for in vitro spermatogenesis.
The company plans to price the procedure between $5,000 and $12,000. This cost, while potentially life-changing for families, raises immediate questions about accessibility. Justin Dubin, a urologist and director of men’s sexual health at Baptist Health Miami Cancer Institute, acknowledged the excitement surrounding Paterna’s advance but cautioned about cost as a limiting factor. “We’re coming up with so many amazing options in fertility care, and yet so many of them are not covered by insurance,” Dubin observed.
For many working families, this could mean the difference between realizing a dream and facing continued heartbreak. The policy says one thing about medical advancement; the reality of insurance coverage says another for many. Beyond current infertility cases, Flannigan suggested Paterna’s technique could also benefit boys undergoing chemotherapy for cancer treatment before puberty.
Sperm-forming stem cells are present from birth. Young cancer patients have had the option to freeze and preserve testicular tissue for years, but transplanting it back remains experimental. No births have been reported using that method.
Paterna’s lab-based approach could offer a more direct route to preserving future fertility for these survivors. This expands the potential impact of the research considerably. Other research efforts in this field focus on induced pluripotent stem cells (iPSCs), which are skin or blood cells reprogrammed to an embryonic-like state.
These iPSCs can then be guided to become any cell type, including sperm or eggs. Scientists have successfully created functional sperm and eggs from mouse pluripotent stem cells, resulting in healthy offspring. This technique, known as in vitro gametogenesis (IVG), theoretically could allow same-sex couples to have biological children by generating gametes from a skin sample.
Paterna's method, by contrast, starts directly with existing testicular stem cells. Paterna has reported a high success rate in generating sperm from dozens of tissue samples. Early testing indicates that the lab-made sperm appear “effectively identical” to naturally produced sperm.
The procedure is not yet ready for use in starting pregnancies. To validate its lab-made sperm, Paterna created embryos as an initial test. The company now plans a larger, more comprehensive study involving men with infertility.
This study will involve extracting sperm from their ejaculate or testicular tissue, and using Paterna's method to generate additional sperm. The research will then compare fertilization rates between the extracted and lab-made sperm, and analyze the resulting embryos for physical and genetic abnormalities. “That will actually tell us a ton regarding the efficacy and safety of the approach. It will tell us if there are any mutations that are created by the in vitro process,” Pastuszak emphasized.
This careful validation is crucial. “It’s a huge disservice to our patients, to the world’s population, by not providing people with the means to achieve the family that they want,” Dubin stated, underscoring the broader societal challenge. What this actually means for your family is that a scientific breakthrough, however promising, faces significant hurdles before it becomes widely accessible. The cost of such cutting-edge treatments often places them out of reach for many.
This disparity highlights a persistent tension between medical innovation and equitable healthcare access. The next steps for Paterna involve moving toward clinical trials for starting pregnancies, which could commence as early as next year, if their validation studies yield positive results. Regulators will then scrutinize the safety and efficacy data closely.
Watch for announcements regarding these human trials and the initial findings from their comprehensive studies. These will determine the pace at which this technology moves from a laboratory success to a practical solution for families facing infertility. The conversation around insurance coverage will also intensify, determining who can truly benefit from this new science. - Paterna Biosciences claims to have grown functional human sperm in a lab from testicular stem cells. - The lab-grown sperm successfully fertilized eggs, producing visibly healthy embryos. - This technology could offer new options for men with complete absence of sperm, a significant portion of male infertility cases. - High costs, estimated between $5,000 and $12,000, may limit accessibility without insurance coverage.
Why It Matters This development represents a potential shift in how male infertility is addressed, moving beyond invasive surgical sperm retrieval or reliance on donor sperm. However, the high price point means that its transformative potential might initially be limited to those with significant financial resources or robust insurance coverage. This raises important questions about equity in access to advanced reproductive technologies, questions that will shape the future landscape of fertility care for families across economic spectrums.
Key Takeaways
— - Paterna Biosciences claims to have grown functional human sperm in a lab from testicular stem cells.
— - The lab-grown sperm successfully fertilized eggs, producing visibly healthy embryos.
— - This technology could offer new options for men with complete absence of sperm, a significant portion of male infertility cases.
— - High costs, estimated between $5,000 and $12,000, may limit accessibility without insurance coverage.
Source: Wired
